Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis - PubMed
3 hours ago
- #urothelial carcinoma
- #meta-analysis
- #antibody-drug conjugates
- Systematic review and meta-analysis examines antibody-drug conjugates (ADCs) for locally advanced/metastatic urothelial carcinoma.
- Evaluated ADCs: enfortumab vedotin, disitamab vedotin, and sacituzumab govitecan in both interventional and observational studies.
- Pooled objective response rate for enfortumab vedotin monotherapy was ~43-44% across study types.
- Enfortumab vedotin plus pembrolizumab showed a pooled ORR of ~67-68% overall.
- Disitamab vedotin plus PD-1 inhibitors had an ORR of ~75% in interventional trials.
- Meta-regression identified prior PD-1/L1 exposure and treatment regimen as factors influencing response.
- Enfortumab vedotin monotherapy showed significant survival advantage over chemotherapy in cisplatin-ineligible patients.
- Enfortumab vedotin-based regimens robust across settings; disitamab vedotin with immunotherapy shows potent activity.